Last updated: February 27, 2026
What is NDC 43598-0552?
NDC 43598-0552 identifies Zolgensma (onasemnogene abeparvovec-xioi), a gene therapy developed by Novartis for spinal muscular atrophy (SMA) types 1, 2, and 3. Approved by the FDA in May 2019, Zolgensma is designed for patients under 2 years old and certain older patients depending on specific criteria.
Market Size and Growth Dynamics
Addressable Patient Population
- SMA prevalence: Roughly 1 in 10,000 live births.
- Estimated US patient base: Approx. 600 to 800 infants yearly, with a total US SMA population estimated at 15,000 to 20,000 across all ages.
- Eligibility: Primarily infants <2 years, with some older children depending on disease progression.
Market Drivers
- Regulatory approvals: Zolgensma approved in over 40 countries, including the US, EU, Japan, and others.
- High-cost therapy: List price is approximately $2.1 million per treatment in the US.
- Treatment paradigm shift: Growing adoption as a one-time curative option replacing ongoing therapies like Spinraza (nusinersen).
Competitive Landscape
| Product |
Approval Year |
Delivery Mode |
Price (USD) |
Key Features |
| Zolgensma |
2019 |
Gene therapy |
2.1 million |
Single infusion, durable |
| Spinraza (nusinersen) |
2016 |
Intrathecal injection |
750,000 per year |
Repeated dosing, established |
Note: Zolgensma possesses a pricing advantage over multiple-dose therapies in terms of cumulative costs but faces reimbursement hurdles due to high upfront price.
Market Trends and Revenue Projections
Historical Revenue Data
| Year |
US Zolgensma Revenue (USD Millions) |
Growth Rate (%) |
| 2020 |
280 |
- |
| 2021 |
550 |
96 |
| 2022 |
870 |
58 |
Source: Novartis financial reports ([1]).
Forecast Assumptions (2023-2027)
- Market penetration: Continued increase as diagnosis rates improve and approvals extend to older SMA patients.
- Pricing and reimbursement: Slight downward pressure due to value-based pricing and payer negotiations.
- Global expansion: Growth in Europe, Asia, and emerging markets.
Projected Revenue (USD Millions)
| Year |
Revenue Projection |
CAGR (%) |
| 2023 |
1,100 |
26 |
| 2024 |
1,400 |
27 |
| 2025 |
1,800 |
28 |
| 2026 |
2,200 |
22 |
| 2027 |
2,600 |
18 |
Assumption: Market growth driven by increased diagnosis, expanded indications, and improved reimbursement.
Price Projections
- Per-treatment price: Remains near $2.1 million barring policy shifts.
- Pricing pressure: Will likely stem from payer negotiations, demand for value-based agreements, and new competing therapies.
Factors Influencing Price and Market Dynamics
- Regulatory changes: Expanding indications may increase total sales but could introduce pricing reductions or negotiated discounts.
- Market access strategies: Novartis employs risk-sharing agreements with payers, leading to potential discounts.
- Pipeline developments: Upcoming gene therapies or biosimilars could influence pricing and market share.
Risks and Challenges
- Reimbursement hurdles: The high upfront cost remains a barrier for certain insurers and patients.
- Manufacturing complexities: Ensuring supply chain stability influences market availability.
- Competitive pressures: Ongoing R&D may yield new therapies impacting Zolgensma's market share.
Conclusion
NDC 43598-0552, Zolgensma, commands a premium due to its status as a one-time curative gene therapy for SMA. Revenue growth is expected to continue driven by expanded indications and geographic reach, although pricing pressures are likely to increase. Payer negotiations and pipeline developments are critical factors determining future price stability and market share.
Key Takeaways
- Zolgensma's US list price of about $2.1 million remains high but is justified by its single-dose curative potential.
- The therapy's market grew sharply from 2020 to 2022, with revenues projected to reach $2.6 billion globally by 2027.
- Reimbursement strategies and pipeline innovations influence long-term pricing and market dynamics.
- Manufacturers face balancing market access with premium pricing due to cost and regulatory challenges.
- Expanding indications to older and newly diagnosed patients could significantly increase the addressable market.
FAQs
1. What factors primarily drive Zolgensma’s revenue growth?
Expanded indications, increased diagnosis rates, geographic expansion, and market acceptance of gene therapy as a treatment paradigm.
2. How does Zolgensma compare price-wise to other SMA treatments?
It typically costs around $2.1 million as a one-time dose, compared to Spinraza’s annual costs of approximately $750,000. Overall, Zolgensma offers a potential lower lifetime cost but is constrained by high upfront pricing.
3. What are the main reimbursement challenges for Zolgensma?
High initial cost, payer approval processes, and risk-sharing agreements influence access and market penetration.
4. How might pipeline developments impact Zolgensma’s market?
New therapies or biosimilars could lower prices and reduce market share, pressuring Zolgensma to adapt pricing and access strategies.
5. Are there targeted geographical markets for future growth?
Yes. Significant growth opportunities exist in Europe, Japan, China, and other emerging markets, driven by regulatory approvals and increasing SMA diagnosis rates.
References
[1] Novartis. (2022). Annual financial report.
